Head and neck cancer and asbestos exposure.


Journal

Occupational and environmental medicine
ISSN: 1470-7926
Titre abrégé: Occup Environ Med
Pays: England
ID NLM: 9422759

Informations de publication

Date de publication:
10 2022
Historique:
received: 02 10 2021
accepted: 19 03 2022
pubmed: 9 4 2022
medline: 17 9 2022
entrez: 8 4 2022
Statut: ppublish

Résumé

The aim of this study was to analyse, within a French cohort of workers previously occupationally exposed to asbestos, incidence and mortality from various sites of head and neck cancers (larynx excluded) and to examine the potential link of these cancers with pleural plaques. A 10-year follow-up study was conducted in the 13 481 male subjects included in the cohort between October 2003 and December 2005. Asbestos exposure was assessed by industrial hygienist analysis of a standardised questionnaire. The final cumulative exposure index (CEI; in equivalent fibres.years/mL) for each subject was calculated as the sum of each employment period's four-level CEI. The number of head and neck cancers recorded by the National Health Insurance fund was collected in order to conduct an incidence study. Complementary analysis was restricted to men who had performed at least one chest CT scan (N=4804). A mortality study was also conducted. We used a Cox model with age as the time axis variable adjusted for smoking, time since first exposure, CEI of exposure to asbestos and pleural plaques on CT scans. We reported a significant dose-response relationship between CEI of exposure to asbestos and head and neck cancers after exclusion of laryngeal cancers, in the mortality study (HR 1.03, 95% CI (1.01 to 1.06) for an increase of 10 f.years/mL) and a close to significant dose-response relationship in the incidence study (HR 1.02, 95% CI (1.00 to 1.04) for an increase of 10 f.years/mL). No statistically significant association between pleural plaques and head and neck cancer incidence was observed. This large-scale study suggests a relationship between asbestos exposure and head and neck cancers, after exclusion of laryngeal cancers, regardless of whether associated pleural plaques were present.

Identifiants

pubmed: 35393288
pii: oemed-2021-108047
doi: 10.1136/oemed-2021-108047
pmc: PMC9484389
doi:

Substances chimiques

Asbestos 1332-21-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

690-696

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Scand J Work Environ Health. 2014 Jul;40(4):420-7
pubmed: 24810833
Int J Cancer. 2004 Sep 20;111(5):757-61
pubmed: 15252847
Am J Ind Med. 2017 Nov;60(11):968-975
pubmed: 28884469
Eur Respir J. 2009 Jul;34(1):72-9
pubmed: 19129281
Occup Environ Med. 1998 Oct;55(10):651-6
pubmed: 9930084
Int J Cancer. 2005 May 1;114(5):806-16
pubmed: 15609302
Am J Respir Crit Care Med. 2014 Dec 15;190(12):1413-20
pubmed: 25383951
Br J Ind Med. 1990 Dec;47(12):810-4
pubmed: 2176805
Am J Ind Med. 2000 Jun;37(6):581-9
pubmed: 10797501
J Occup Environ Med. 2012 Jan;54(1):71-84
pubmed: 22157731
Am J Ind Med. 1997 Sep;32(3):205-10
pubmed: 9219648
Br J Ind Med. 1989 Feb;46(2):90-6
pubmed: 2923830
Thorax. 2011 Nov;66(11):985-91
pubmed: 21724747
Environ Health Perspect. 2017 Mar;125(3):409-415
pubmed: 27517294
Occup Med (Lond). 2007 Sep;57(6):438-43
pubmed: 17591601
Int Arch Occup Environ Health. 2012 May;85(4):341-51
pubmed: 21785866
IARC Monogr Eval Carcinog Risks Hum. 2007;89:1-592
pubmed: 18335640
Am J Respir Crit Care Med. 2010 Aug 15;182(4):526-30
pubmed: 20442438
Lancet Oncol. 2009 May;10(5):453-4
pubmed: 19418618
Occup Environ Med. 1998 Jun;55(6):393-400
pubmed: 9764099
Br J Ind Med. 1986 Feb;43(2):91-5
pubmed: 3947574
IARC Monogr Eval Carcinog Risks Hum. 1990;49:1-648
pubmed: 2232124
Occup Environ Med. 2013 Dec;70(12):858-63
pubmed: 24142981

Auteurs

Bénédicte Clin (B)

CHU, Caen, France benedicte.clin14@orange.fr.
Université de Caen Normandie, Caen, France.
INSERM U1086 ANTICIPE, Caen, France.

Celine Gramond (C)

Epicene Team, UMR U1219 - Bordeaux Population Health Research Center, Bordeaux, France.

Isabelle Thaon (I)

INGRES, EA 7298, Université de Lorraine, Vandoeuvre les Nancy, France.
Centre de Consultations de Pathologie professionnelle, CHU de Nancy, Vandoeuvre les Nancy, France.

Patrick Brochard (P)

Université de Bordeaux, Bordeaux, France.

Fleur Delva (F)

Environmental Health Platform Dedicated to Reproduction, ARTEMIS Center, Bordeaux University Hospital, Bordeaux, France.
Bordeaux Population Health Research Center, Inserm UMR1219-EPICENE, University of Bordeaux, Talence, France.

Soizick Chammings (S)

CHIC, Creteil, Île-de-France, France.

Antoine Gislard (A)

Service des Maladies Professionnelles, CHU, Rouen, France.

François Laurent (F)

Radiology, Université de Bordeaux, Pessac, France.

Christophe Paris (C)

CHU Rennes, Rennes, Bretagne, France.

Aude Lacourt (A)

Epicene Team, UMR U1219 - Bordeaux Population Health Research Center, Bordeaux, France.

Jean-Claude Pairon (JC)

Pneumologie et Pathologie Professionnelle, Centre Hospitalier Intercommunal de Créteil, Créteil Cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH